Welcome to our dedicated page for Primerica SEC filings (Ticker: PRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Primerica, Inc. filings document operating results and governance matters for a financial services company built around term life insurance and investment and savings product distribution. Recent 8-K reports furnish quarterly results and non-GAAP measures such as adjusted operating revenues, adjusted operating income, adjusted net operating income, diluted adjusted operating earnings per share, and adjusted stockholders’ equity, including treatment of IPO coinsurance transactions and investment gains or losses.
Proxy and governance filings cover director elections, executive compensation, pay-versus-performance data, board matters, and stockholder voting procedures. Other current reports document bylaw provisions for stockholder-requested special meetings and board composition disclosures.
Primerica director Joel M. Babbit reported a non-derivative acquisition on 09/15/2025 that added 28.6055 shares of phantom stock through automatic reinvestment of dividends under the Non-Employee Directors' Deferred Compensation Plan. Phantom stock converts one-for-one into common stock. The filing shows a reported price of $274.23 per share and indicates Mr. Babbit now beneficially owns 9,100.3759 shares (direct). The transaction was reported on Form 4 and signed on 09/16/2025 by an attorney-in-fact.
Insider sale by Primerica President Peter W. Schneider. The Form 4 shows Mr. Schneider executed a sale of 2,000 shares of Primerica, Inc. (PRI) on 08/18/2025 at an average price of $261.1649, with reported trade prices ranging from $259.64 to $262.48. After the sale he beneficially owned 9,301 shares, reported as direct ownership.
The filing indicates the transaction was made pursuant to a 10b5-1 trading plan (box checked). The Form 4 was signed by an attorney-in-fact, Stacey K. Geer, on 08/19/2025. No derivative transactions or other securities classes are reported.
Form 144 filed for Primerica, Inc. (PRI) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $1,046,680.00. The shares were originally acquired as restricted stock awards on 02/21/2015. The filer previously sold 2,000 shares on 05/19/2025 under a 10b5-1 plan, generating gross proceeds of $560,739.40. The filing lists 32,391,333 shares outstanding for the issuer and states the sale will occur on the NYSE.
Primerica reported a Form 4 showing that Glenn J. Williams, who is listed as both a director and the Chief Executive Officer, disposed of shares on 08/12/2025. The filing records a sale of 2,500 shares of Common Stock at a weighted average price of $262.2035. After the reported sale, Mr. Williams is shown as beneficially owning 36,391.995 shares directly. The transaction is coded as a sale and the form was executed on 08/12/2025 by Stacey K. Geer as attorney in fact. The filer explains the weighted average reflects multiple trade prices ranging from $259.22 to $264.34.
Primerica, Inc. (PRI) filed a Form 144 notifying a proposed sale of 2,500 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an indicated aggregate market value of $645,675.00. The shares were acquired as Restricted Stock Units on 03/01/2025 and the filing lists an approximate sale date of 08/12/2025. The filing also discloses a prior 10b5-1 sale of 2,500 shares on 06/13/2025 generating gross proceeds of $647,591.25. Outstanding shares are shown as 32,391,333, making the proposed block a very small percentage of the company.
Primerica Q2 2025 10-Q highlights
- Revenue inched up 0.3% YoY to $793.3 million; commissions & fees rose 14% while net premiums grew 3.6%.
- Pre-tax income from continuing ops fell 14% to $234.5 million; net income declined to $178.3 million (-15%) as prior-year results contained a one-off $50 million insurance recovery.
- Diluted EPS from continuing ops dropped to $5.40 (-11%); total diluted EPS unchanged by discontinued Senior Health unit, which caused a $208 million loss in Q2 2024.
- Segment performance: Term Life pre-tax profit +5% to $155.0 million; Investment & Savings Products +6% to $79.4 million; Corporate & Other near breakeven versus $50.2 million profit last year.
- Capital returns: 2Q buybacks of $127 million and dividends of $34 million reduced diluted share count 4% YoY to 32.9 million; YTD repurchases total $251 million.
- Balance sheet: Assets $14.83 b (+2% YTD); equity $2.31 b (+2%). Cash fell to $621 million after $329 million financing outflows. AOCI improved by $63 million YTD on discount-rate and FX movements.
- Liquidity & cash flow: Operating cash flow solid at $360 million versus $384 million YTD 2024; investing cash outflow $100 million driven by portfolio reinvestment.
Bottom line: Core franchises showed modest growth, but elevated expenses and loss of 2024’s non-recurring gain compressed margins. Shareholder payouts remain aggressive, sustaining mid-teens ROE.